The potential roles of antibody-drug conjugates in head and neck squamous cell carcinoma
- 7 February 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 36 (3) , 147-154
Abstract
Purpose of review: To summarize the actual antibody-drug conjugates (ADCs) tested for patients with advanced head and neck squamous cell carcinoma (HNSCC), outlining the results of safety and efficacy through published clinical trials. Recent findings: ADCs combine the specificity of mAbs with the cytotoxic drug (known as payload) via a chemical linker and it is designed to selectively deliver the ultratoxic payload directly to the target cancer cells. To date, various ADCs have been investigated in multiple solid malignancies and others are in clinical development. In this study, we provide an overview of the structure and biology of ADC and we review recent clinical experience with the ADC in patients with advanced HNSCC, followed by a brief discussion of the evolvement of ADC conception, drug resistance and future perspectives. Summary: ADC strategy is emerging as a potential active treatment in previously treated patients with advanced HNSCC. However, the recent improvement in the bioengineering of ADC and a better comprehension of sequencing and association strategies could provide more benefit to HNSCC patients in need of innovative therapy.Keywords
This publication has 39 references indexed in Scilit:
- Tisotumab vedotin in recurrent or metastatic cervical cancerCurrent Problems in Cancer, 2023
- Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid TumorsJAMA Oncology, 2022
- Antibody drug conjugate: the “biological missile” for targeted cancer therapySignal Transduction and Targeted Therapy, 2022
- A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRInvestigational New Drugs, 2020
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Antibody–drug conjugates for cancerThe Lancet, 2019
- Strategies and challenges for the next generation of antibody–drug conjugatesNature Reviews Drug Discovery, 2017
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugatesJournal of Pharmacokinetics and Pharmacodynamics, 2016
- Challenges and advances in the assessment of the disposition of antibody‐drug conjugatesBiopharmaceutics & Drug Disposition, 2015
- Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinomaOral Oncology, 2008